Can GLP-1 drugs treat Alzheimer’s? Novo Nordisk will soon announce key results

Taking stock of the drug industry, from the lab to the medicine chest

November 19, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

MADS CLAUS RASMUSSEN/Ritzau Scanpix/AFP via Getty Images STAT+ | Can GLP-1 drugs treat Alzheimer's? Novo Nordisk will soon announce key results Novo Nordisk will soon release results of ambitious studies on whether its GLP-1 drug semaglutide can help slow the progression of Alzheimer's disease. By Elaine Chen STAT+ | Pfizer and Tris agree to $41.5 million settlement with Texas over ADHD drug for children The lawsuit contended the drugmakers were aware of the problems with the drug but made misrepresentations to state Medicaid officials. By Ed Silverman STAT+ | Agios reports mixed results from sickle cell study, raising doubts about drug's future The study succeeded on one primary endpoint but failed on another, raising doubts about whether the drug could win approval in sickle cell. By Adam Feuerstein Patrick Sison/AP STAT+ | An extension of extra ACA health insurance subsidies looks increasingly unlikely Enhanced ACA subsidies, key issue behind the government shutdown, appear unlikely to be extended. Democrats need 13 GOP senators to agree on a plan. By John Wilkerson

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser